Judge Dismisses Antitrust MDL Against Ranbaxy and Pfizer Over Lipitor Pricing After Speculative Claims

Multiple Ranbaxy Inc. entities have overcome a multidistrict litigation (MDL) accusing them of conspiring with Pfizer Inc. to delay the release of a generic alternative to the blood pressure drug Lipitor. A New Jersey federal judge criticized the drug purchasers’ arguments as “speculative,” ultimately leading to a dismissal of the case. For more details on the ruling, please refer to the report by Law360.